These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
625 related articles for article (PubMed ID: 15871762)
21. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective? Lien K; Berry S; Ko YJ; Chan KK Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031 [TBL] [Abstract][Full Text] [Related]
22. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. You B; Chen EX J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284 [TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
24. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Ng K; Zhu AX Crit Rev Oncol Hematol; 2008 Jan; 65(1):8-20. PubMed ID: 18006328 [TBL] [Abstract][Full Text] [Related]
25. [Targeting the epidermal growth factor receptor in colorectal cancer: clinical results]. Adenis A; Hebbar M Bull Cancer; 2005 Aug; 92(Spec no):S21-8. PubMed ID: 16387666 [TBL] [Abstract][Full Text] [Related]
26. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Peeters M; Price T; Van Laethem JL Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681 [TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068 [TBL] [Abstract][Full Text] [Related]
28. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Van Cutsem E Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643 [TBL] [Abstract][Full Text] [Related]
29. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142 [TBL] [Abstract][Full Text] [Related]
30. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711 [TBL] [Abstract][Full Text] [Related]
31. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Blackledge G; Averbuch S Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365 [TBL] [Abstract][Full Text] [Related]
32. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cunningham MP; Thomas H; Fan Z; Modjtahedi H Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373 [TBL] [Abstract][Full Text] [Related]
36. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749 [TBL] [Abstract][Full Text] [Related]
37. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target. Gaffney DC; Soyer HP; Simpson F Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099 [TBL] [Abstract][Full Text] [Related]
38. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023 [TBL] [Abstract][Full Text] [Related]
39. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. Venook AP J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248 [TBL] [Abstract][Full Text] [Related]
40. [Cutaneous side effects of EGFR inhibitors--appearance and management]. Wollenberg A; Kroth J; Hauschild A; Dirschka T Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]